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Objectives The aim of this study was to assess the (cost-) effectiveness of screening asymptomatic individuals at intermedi-
ate risk of coronary heart disease (CHD) for coronary artery calcium with computed tomography (CT).
Background Coronary artery calcium on CT improves prediction of CHD.
Methods A Markov model was developed on the basis of the Rotterdam Study. Four strategies were evaluated: 1) current
practice; 2) current prevention guidelines for cardiovascular disease; 3) CT screening for coronary calcium; and
4) statin therapy for all individuals. Asymptomatic individuals at intermediate risk of CHD were simulated over
their remaining lifetime. Quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratios
were calculated.
Results In men, CT screening was more effective and more costly than the other 3 strategies (CT vs. current practice: 0.13
QALY [95% confidence interval (CI): 0.01 to 0.26], $4,676 [95% CI: $3,126 to $6,339]; CT vs. statin therapy: 0.04
QALY [95% CI: 0.02 to 0.13], $1,951 [95% CI: $1,170 to $2,754]; and CT vs. current guidelines: 0.02 QALY
[95% CI: 0.04 to 0.09], $44 [95% CI: $441 to $486]). The incremental cost-effectiveness ratio of CT calcium
screening was $48,800/QALY gained. In women, CT screening was more effective and more costly than current prac-
tice (0.13 QALY [95% CI: 0.02 to 0.28], $4,663 [95% CI: $3,120 to $6,277]) and statin therapy (0.03 QALY
[95% CI: 0.03 to 0.12], $2,273 [95% CI: $1,475 to $3,109]). However, implementing current guidelines was
more effective compared with CT screening (0.02 QALY [95% CI: 0.03 to 0.07]), only a little more expensive
($297 [95% CI: $8 to $633]), and had a lower cost per additional QALY ($33,072/QALY vs. $35,869/QALY). Sen-
sitivity analysis demonstrated robustness of results in women but considerable uncertainty in men.
Conclusions Screening for coronary artery calcium with CT in individuals at intermediate risk of CHD is probably cost-effective
in men but is unlikely to be cost-effective in women. (J Am Coll Cardiol 2011;58:1690–701) © 2011 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.05.056In asymptomatic individuals, primary prevention of cor-
onary heart disease (CHD) is often based on the pre-
dicted 10-year risk of a CHD event. The Framingham
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Guidelines on cardiovascular disease (CVD) prevention
recommend advice on a healthy lifestyle (e.g., smoking
cessation, regular physical activity) for individuals with a
See page 1702
low CHD risk (10%, 10-year risk), supplemented by
statins, antihypertensive medication, and sometimes as-
pirin for individuals at high CHD risk (20%, 10-year
risk) (3–5). In individuals at intermediate risk (10%
to 20%, 10-year risk), the decision to treat with drugs
is generally only recommended when either serum cho-
lesterol or blood pressure levels are above a defined
threshold. In this group, performing a noninvasive test
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from more aggressive treatment. Coronary artery calcium
on computed tomography (CT), quantified by the CT
coronary calcium score, is such a test (6,7).
Recent studies have demonstrated that the CT calcium
score is a strong predictor of CHD risk, independent of
the Framingham risk factors (7–16). In fact, more than
one-half of the individuals originally classified at inter-
mediate risk, on the basis of the Framingham risk factors,
are reclassified to the high-risk (20%) or low-risk
(10%) category when the calcium score is taken into
account (7,17). Accordingly, these individuals should be
treated more aggressively (high risk) or less aggressively
(low risk). The reclassification to another risk category
suggests that using CT might be beneficial but reclassi-
fication by itself is insufficient evidence to justify imple-
mentation (18,19). Studies, ideally clinical trials, demon-
strating comparative effectiveness and cost-effectiveness
are necessary.
In the absence of clinical trials showing the benefit of
CT screening, an extensive evaluation of CT coronary
calcium scoring with observational data is warranted (20).
The objective of this study was to assess the comparative
effectiveness and cost-effectiveness of screening an
asymptomatic elderly population at intermediate risk for
CHD for coronary calcium with CT.
Figure 1 Strategy Diagram
Schematic representation of the 4 alternative strategies modeled for an individual
computed tomography (CT) coronary calcium screening, current practice, current g
SBP  systolic blood pressure.Methods
We developed a Markov decision
model with TreeAge for Health
Care (TreeAge Pro 2009, Tree-
Age Software, Williamstown,
Massachusetts) to analyze rele-
vant strategies in asymptomatic
elderly individuals at intermedi-
ate risk for CHD. The model
structure, model parameters, and
data sources are briefly described
here. Details of the modeling
assumptions and parameter esti-
mation are given in the Online
Appendix.
Model structure. The following
4 strategies were considered
(Fig. 1):
1. “Current practice.” This strategy reflects the incidence
of CHD and non-CHD events of individuals at
intermediate risk without any additional preventive
intervention, as observed in the Rotterdam Study, and
is used as the reference strategy. Some individuals
were treated at baseline with statins, antihypertensive
medication, or aspirin by their general practitioners—
ermediate risk for coronary heart disease (CHD):
es, and statin therapy. LDL  low-density lipoprotein;
Abbreviations
and Acronyms
CHD  coronary heart
disease
CI  confidence interval
CT  computed
tomography
CVD  cardiovascular
disease
ICER  incremental cost-
effectiveness ratio
LDL  low-density
lipoprotein
QALY  quality-adjusted
life year
SBP  systolic blood
pressureat int
uidelin
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Cost-Effectiveness of CT Calcium Screening October 11, 2011:1690–701Data Included in the Markov Model on CHD Primary Prevention Strategies forAsymptomatic Elderly Men and Women Identified as B ing at Inte m diate Risk for a CHD EventTable 1 Data Included in the Markov Model on CHD Primary Prevention Strategies forAsymptomatic Elderly Men and Women Identified as Being at Intermediate Risk for a CHD Event
Parameters: Probabilities and Characteristics of
Reclassification Groups
Base-Case Value Men*
(n  329)
Base-Case Value Women*
(n  247) Distribution Data Source† Ref. #
Individuals reclassified to low-risk group
n (%) 101 (31% [26% to 35%]) 95 (38% [33% to 45%]) Beta Cohort study (17)
Observed 10-yr CHD risk 0.05 (0.02 to 0.12) 0.08 (0.04 to 0.16) Beta Cohort study (17)
Observed 10-yr stroke risk 0.05 (0.02 to 0.12) 0.12 (0.04 to 0.16) Beta Cohort study (17)
Individuals not reclassified‡
n (%) 148 (45% [40% to 50%]) 98 (40% [34% to 46%) Beta Cohort study (17)
Observed 10-yr CHD risk 0.10 (0.06 to 0.17) 0.15 (0.09 to 0.25) Beta Cohort study (17)
Observed 10-yr stroke risk 0.06 (0.03 to 0.12) 0.12 (0.04 to 0.12) Beta Cohort study (17)
Individuals reclassified to high-risk group
n (%) 80 (24% [20% to 29%]) 54 (22% [17% to 27%]) Beta Cohort study (17)
Observed 10-yr CHD risk 0.30 (0.21 to 0.43) 0.23 (0.13 to 0.38) Beta Cohort study (17)
Observed 10-yr stroke risk 0.16 (0.09 to 0.28) 0.14 (0.05 to 0.24) Beta Cohort study (17)
First-year CHD-related mortality after a CHD event§ 0.18 (0.13 to 0.22) Beta Cohort study (22)
RR of recurrent CHD event§ 1.5 (1.13 to 1.9) Triangular Cohort study (26)
First-year stroke-related mortality after a stroke event§ 0.20 (0.15 to 0.26) Beta Cohort study (28)
RR of recurrent stroke event§ 2 (1.5 to 2.5) Triangular Cohort study (28)
Lifetime risk of developing cancer due to radiation
associated with CT coronary calcium scanning
0.00008 (0.00005 to 0.00012) 0.00020 (0.00014 to 0.00028) Uniform Simulation study (29)
1-year case fatality given cancer due to radiation risk 0.65 (0.61 to 0.73) 0.70 (0.63 to 0.78) Triangular Simulation study (27)
Treatment effectiveness of statins
RR on incident CHD, statins vs. placebo§ 0.70 (0.61 to 0.81) Log normal Meta-analysis (24)
RR on incident stroke, statins vs. placebo§ 0.81 (0.71 to 0.93) Log normal Meta-analysis (24)
Cost of statins, yearly§ $570 Pharmacy reference (33)
RR of hepatitis, statins vs. placebo 3.51 6.5 Log normal Meta-analysis (42)
RR of myopathy, statins vs. placebo 1.53 1.53 Log normal Meta-analysis (42)
Expected cost of hepatitis episode§ $120 Cohort study (43)
Expected cost of myopathy episode§ $250 Cohort study (43)
Expected disutility of hepatitis episode§ 0.05 QALY Cohort study (43)
Expected disutility of myopathy episode§ 0.025 QALY Cohort study (43)
Treatment effectiveness of antihypertensives
RR of incident CHD, antihypertensives vs. placebo§ 0.85 (0.81 to 0.89) Log normal Meta-analysis (30)
RR of incident stroke, antihypertensives vs. placebo§ 0.64 (0.56 to 0.73) Log normal Meta-analysis (30)
Cost of antihypertensives, yearly§ $670 Pharmacy reference (33)
Treatment effectiveness of aspirin
RR of incident CHD, aspirin vs. placebo 0.82 (0.75 to 0.90) Log normal Meta-analysis (38)
RR of incident stroke, aspirin vs. placebo 0.95 (0.85 to 1.06) Log normal Meta-analysis (38)
Annual rate major extracranial bleeding 0.0010 (0.00096 to 0.0012) Log normal Meta-analysis (38)
RR of major extracranial bleeding 1.54 (1.30 to 1.82) Log normal Meta-analysis (38)
1-yr case fatality due to major extracranial bleeding§ 0.03 (0.02 to 0.04) Log normal Estimate (28)
Cost of aspirin, yearly§ $20 Pharmacy reference (33)
Synergy factor 1 (0.9 to 1.1) 1 (0.9 to 1.1) Uniform See text
Utilities
Asymptomatic elderly 0.86 (0.85 to 0.86) 0.83 (0.83 to 0.84) Normal Survey (32)
Post-CHD event 0.76 (0.74 to 0.77) 0.67 (0.65 to 0.69) Normal Survey (32)
Post-major bleeding 0.72 (0.70 to 0.74) 0.67 (0.65 to 0.69) Normal Survey (32)
Post-stroke event 0.69 (0.67 to 0.71) 0.61 (0.59 to 0.63) Normal Survey (32)
Disutility due to CHD event 0.10 (0.13 to 0.08) 0.16 (0.20 to 0.12) Triangular Survey (32)
Disutility due to major bleeding 0.14 (0.10 to 0.17) 0.16 (0.20 to 0.12) Triangular Survey (32)
Disutility due to stroke event 0.19 (0.24 to 0.16) 0.22 (0.26 to 0.19) Triangular Survey (32)Continued on next page
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CHD and stroke.
2. “Current guidelines.” This strategy, based on fully
implementing the most recent guidelines on primary
prevention of CHD for individuals at intermediate
risk for CHD, implies giving lifestyle advice to all,
statin therapy when baseline low-density lipoprotein
(LDL) cholesterol exceeds 130 mg/dl (3.37 mmol/l)
(4), and antihypertensive medication when baseline
systolic blood pressure exceeds 140 mm Hg (5). In a
sensitivity analysis, we lowered the LDL threshold to
100 mg/dl (2.59 mmol/l).
3. “CT calcium screening.” In this strategy a CT scan
was performed to determine the coronary calcium
score, and the 10-year CHD risk was recalculated on
the basis of the Framingham risk factors and the
calcium score combined. Consequently, a number of
individuals will be reclassified to the high-risk or
low-risk category. Individuals reclassified to the low-
risk category received lifestyle advice and pharmaco-
logical treatment if systolic blood pressure was above
140 mm Hg (21) and/or plasma LDL levels were
160 mg/dl (4.14 mmol/l) (4). Individuals who re-
mained in the intermediate-risk category were treated
as recommended for individuals at intermediate risk,
similar to strategy 2. Individuals reclassified to the
high-risk group received lifestyle advice, statin ther-
apy, and antihypertensive medication, irrespective of
their baseline cholesterol and blood pressure levels. In
addition, men received low-dose aspirin (80 to 100 mg
daily). For both the current guidelines and CT cal-
cium screening strategy, we assumed that individuals
who used any of the 3 drugs at baseline would
continue to use them.
4. “Statin therapy.” For this strategy we assumed that
everyone not currently taking a statin would receive a
moderate-dose statin and would be otherwise man-
aged according to “current practice.” Although initi-
ContinuedTable 1 Continued
Parameters: Probabilities and Characteristics of
Reclassification Groups
Base-Case Value M
(n  329)
Costs, $
Performing a CT coronary calcium score§ $105 ($85 to $12
First-year costs of CHD event§ $21,233 ($17,196 to $2
First-year costs of stroke event $24,000 ($18,000 to $3
First-year costs of major extracranial bleeding§ $13,400 ($10,500 to $2
Annual follow-up post-CHD or stroke event§ $1,330 ($1,006 to $1
Adherence, reference case analysis 70% (40% to 100%
Data included in the Markov model on coronary heart disease (CHD) primary prevention strategies f
risk 10% to 20%). Risk group classification, associated risk prediction, and prevalence of medic
Calcification Study). Major bleeding is defined as hemorrhagic stroke, gastrointestinal bleeding. *
for the triangular and uniform distributions. †Risk group classification, associated risk prediction,
Rotterdam Coronary Calcification Study). ‡Individuals stayed in intermediate-risk group. §Risk of
2010 U.S. dollars.
CT  computed tomography; RR  relative risk.ating statins in all individuals is not always considered efeasible in all situations, it puts the CT calcium
screening strategy into a broader perspective, between
the least aggressive strategy (“current practice”) and
fairly aggressive strategy (“statin therapy”), providing a
range of possibilities for an individual at intermediate
risk of CHD (20). Conceptually, an even more ag-
gressive strategy would be to treat everyone not only
with statins but also with antihypertensive medication
and aspirin (in men). In a sensitivity analysis, we
substituted the statin therapy strategy with this “ag-
gressive medical treatment” strategy.
For each of the 4 strategies, the model kept track of
uality of life, costs, and time spent in 1 of the following
ealth states: 1) well; 2) after CHD event; 3) after major
leeding; 4) after stroke event; 5) after stroke event and
HD event; 6) after stroke and major bleeding; 7) after
HD event and major bleeding; 8) after CHD event and
troke event and major bleeding; 9) CHD or stroke death;
nd 10) non-CHD or nonstroke death. Each simulated
ndividual started out in the “well” state. Age- and sex-
pecific probabilities of non-CHD death, fatal and nonfatal
yocardial infarction, fatal and nonfatal major bleeding due
o aspirin use, fatal and nonfatal stroke, and lethal cancer
ue to radiation determined the transition to the other states
uring each annual cycle. The time horizon was the remain-
ng lifetime of the simulated individuals.
A CHD event was defined as any of the following
utcomes: nonfatal myocardial infarction, coronary artery
ypass graft, percutaneous coronary intervention, and CHD
ortality. In sensitivity analysis, we repeated the analysis
ith “hard” CHD events as outcome, consisting of nonfatal
yocardial infarction and CHD mortality. Stroke was
efined as ischemic, hemorrhagic, or undefined stroke on
erebral CT. Major bleeding due to aspirin therapy (defined
s extra cranial hemorrhage leading to substantial disability)
as modeled as a secondary event.
After a CHD event, stroke event, or a major bleeding
Base-Case Value Women*
(n  247) Distribution Data Source† Ref. #
Triangular Official tariff See text
) Gamma Cost study (45)
) Gamma Cost study (56)
) Gamma Cost study (31,34)
Gamma Cost study (46,56)
Uniform Expert opinion See text
ptomatic elderly men and women identified as being at intermediate risk for a CHD event (10-year
se at baseline are based on a prospective observational cohort study (the Rotterdam Coronary
parentheses are 95% confidence intervals for the beta- and (log)normal distributions and ranges
valence of medication use at baseline are based on a prospective observational cohort study (the
probabilities, utilities, and cost estimates described for men are identical for women. Costs areen*
5)
5,207
0,000
3,450
,601)
)
or asym
ation u
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tively, or the combined states if 2 or all 3 events occurred.
After a major bleeding episode, we assumed that aspirin
therapy would be discontinued. In the case of a nonfatal
CHD or stroke, individuals would be allocated medical
treatment for secondary CVD prevention. Non-CHD
deaths included fatal cancer due to radiation associated with
CT scanning.
Data sources. Effectiveness of treatment, cost data, and
transition probabilities were retrieved from published liter-
ature and primary data collection and summarized in Table
1 with their data sources (17,22–34).
Rotterdam Study and event rates. From 1997 onwards,
2,028 participants in the Rotterdam Study underwent CT
to determine their coronary calcium score and were subse-
quently followed for 9.2 years (median) (12,17,35). Primary
care physicians were blinded for the findings on CT.
Interobserver and intraobserver agreement on calcium scor-
ing has been found to be excellent (36). Two regression
models were developed to predict the 10-year risk of CHD
on the basis of the Framingham risk factors (prediction
model 1) and on the basis of Framingham plus the coronary
calcium score (prediction model 2) (17). The Framingham
risk factors included were: age, systolic blood pressure,
antihypertensive medication, total and high-density lipo-
protein cholesterol, diabetes, and current smoking (4). More
than 50% of the individuals classified as Framingham
intermediate-risk patients were reclassified to either high-
or low-risk when CT coronary calcium was added as risk
factor and the C-statistic increased significantly from 0.72
to 0.76 (17). The net improvement in reclassification was
found to be 0.14 (p  0.01).
After excluding individuals who had a history of CHD or
troke before the CT coronary calcium scan, we used the
aseline Rotterdam Study data and the 2 prediction models
o: 1) determine the baseline characteristics of the target
opulation; and 2) determine the proportion of Framing-
am intermediate-risk individuals reclassified to low and
igh risk when the coronary calcium score was added. Of all
ndividuals reclassified to the low-, intermediate-, or high-
isk categories, we observed how many of them actually
uffered from a CHD or stroke event with survival analysis
tratified by sex (Table 1).
Probabilities of having a non-CHD event were calculated
n the basis of age- and sex-specific mortality rates from
ational life tables of the general population (37). Life
xpectancy was adjusted for quality-of-life with mean
ealth-related quality-of-life weights on the basis of pub-
ished data (Table 1) (32).
ffectiveness of treatment. The benefit of statin and
antihypertensive treatment on CHD and stroke incidence
was obtained from meta-analyses and considered equal for
men and women (24,30). On the basis of a recent update,
there is evidence that elderly men benefit from aspirin
therapy in primary prevention of CHD. For elderly women
there remains considerable controversy (3). Therefore, as- cpirin treatment for primary prevention was, when applica-
ble, only modeled in men (38).
Treatment adherence is an important determinant of treat-
ment benefit (39). Although we used intention-to-treat-based
relative risk reductions on the basis of clinical trials, which take
into account adherence, the adherence rate in a population-
based intervention is less than that achieved in the controlled
setting of a trial. We assumed, on the basis of expert opinion,
adherence to treatment in our population to be 70% of the
adherence in the original trials for the reference case analysis
and explored a range of 20% to 100% in a sensitivity analysis.
For secondary prevention and primary prevention in
high-risk individuals, statins, antihypertensive medication,
and—in men—aspirin therapy, are combined. Wald and
Law (40) estimated the effect of combining medication for
CHD prevention, but their approach does not account for
possible synergy or dyssynergy between the drugs (41).
Instead, we estimated the effect of combining drugs by
multiplying the individual relative risks and multiplying the
product by a synergy factor, which we varied in sensitivity
analyses between 0.9 and 1.10—0.9 implying synergy, 1.0
implying independent effects, and 1.10 implying dyssynergy
(see Online Appendix for details). The range in the synergy
factor was chosen such that a combination of drugs was at
least as effective as a single component of the combination
of the same drugs.
Because we considered a population at intermediate risk,
we accounted for the fraction of individuals that used (a
combination of) statins, aspirin, or antihypertensive medi-
cation at baseline. An individual using statins at baseline but
with LDL cholesterol levels 160, 130, and 90 mg/dl
for the low-, intermediate-, and high-risk categories, re-
spectively, was assumed to switch to a higher dose or more
potent statin. The same was assumed for an individual using
antihypertensive medication at baseline and systolic blood
pressure levels 140 mm Hg, 140 mm Hg, and 120
m Hg for the 3 risk categories, respectively.
We assumed that all individuals in the Rotterdam Coronary
alcium Study received lifestyle advice consistent with current
rimary care practice and therefore that the observed CHD
nd stroke event rates reflected this intervention.
dverse effects. Hemorrhagic stroke due to aspirin therapy
as accounted for in the odds ratios of net treatment benefit
or stroke from the meta-analysis. Extracranial major bleed-
ng due to aspirin therapy was modeled explicitly as a
econdary event with probabilities on the basis of a recent
eta-analysis (23). Myopathy and hepatitis were modeled
n the basis of a meta-analysis of the adverse effects of
tatins (42). On the basis of a recent modeling study by
letcher et al. (43), we calculated the expected costs and
isutilities of a myopathy and hepatitis episode, including
osts for associated complications such as hospital admis-
ion, workup, and mortality, weighted by the probability of
omplications.
osts. Costs incorporated in the model included healthcareosts and non-healthcare costs and were assessed from the
 low
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were converted to the year 2010 with the consumer price
indexes.
Healthcare costs included costs of diagnostic procedures;
costs for personnel, materials, and equipment; costs for med-
ication; costs for healthcare resource use in subsequent years
after an event; and costs for overhead. The costs for a
noncontrast cardiac CT were based on healthcare reimburse-
ment rates in 2009. Medication costs were based on pricing
information from the 2009 Red Book (33), which were
comparable with current prices for statins, antihypertensive
medication, and aspirin. We assumed, on the basis of baseline
LDL cholesterol, that 30% of our population would need a
potent and more expensive statin, such as rosuvastatin or
atorvastatin, and the remaining 70% could do with a generic
statin such as simvastatin. For antihypertensive medication we
assumed that everyone would need at least a thiazide, com-
bined with an angiotensin II receptor blocker, angiotensin-
Baseline Characteristics of Study PopulationWith I itial Risk of CHD Between 10% and 20%Table 2 B seline Charact ristics of Study PWith Initial Risk of CHD Between 1
Variable Men
Age, yrs 70
Body mass index, kg/m2 26.5
Systolic blood pressure, mm Hg 144
Diastolic blood pressure, mm Hg 78
Total cholesterol, mg/dl [mmol/l] 222 (201–2
HDL cholesterol, mg/dl [mmol/l] 46 (33–63
LDL cholesterol, mg/dl [mmol/l] 146 (124–16
Cholesterol-lowering medication 52
Antihypertensive medication 87
Antithrombotic agents 97
Smokers
Never 2
Current 7
Former 23
Diabetes mellitus 19
Calcium score
0 1
1–100 12
101–400 7
401–1,000 6
1,000 5
Values are mean (interquartile range) or n (%).
CHD  coronary heart disease; HDL  high-density lipoprotein; LDL
Cost, Clinical Effectiveness, and Cost-Effectiveness of Strategies fTable 3 Cost, Clinical Effectiveness, and Cost-Effectiveness of
Total Lifetime Costs*†
Quality-Adjusted
Life Expectancy* (yrs)
Current practice 7,551 10.03
Statin therapy 10,276 10.12
Current guidelines 12,184 10.14
CT screening 12,228 10.16
Cost, clinical effectiveness, and cost-effectiveness of strategies for asymptomatic men (mean ag
Strategies ordered by increasing cost. *Future costs and life years were discounted at 3%/year. †2
incremental cost-effectiveness ratios compared with both “current practice” and the next-best strate
[CT] screening) that yields higher effectiveness at a lower incremental cost-effectiveness ratio.
QALY  quality-adjusted life year.converting enzyme inhibitor, or calcium channel blocker in
60% of individuals (44). Medication costs were only accounted
for in adherent individuals. In a sensitivity analysis, we used
generic prices for statins and antihypertensive medication,
estimated to be $160 yearly for generic statins and $300 for
antihypertensive medication (33). For both strategies 2 and 3,
we accounted for the costs of obtaining the Framingham risk
factors by a general practitioner, including laboratory costs.
Event-related costs included the costs of hospital stay, diag-
nostic workup, interventions, and rehabilitation during the first
year after an event and were assumed to reflect the average cost
after a nonfatal myocardial infarction, coronary artery bypass
graft, or percutaneous coronary intervention (31,34,45,46).
Non-healthcare costs included travel costs and patient time
costs.
Analysis. All authors agreed on the model structure and
data input before performing the analyses to ensure an
objective and unbiased analysis.
tion
nd 20%
29) Women (n  247)
3) 74 (71–78)
28.7) 28 (25–31)
55) 149 (135–161)
5) 76 (69–82)
7 (5.2–6.2)] 240 (217–232) [6.2 (5.6–6.8)]
(1.1–1.4)] 50 (39–54) [1.3 (1.1–1.4)]
5 (2.42–5.1)] 158 (135–178) [4.1 (2.63–5.62)]
%) 44 (17.8%)
%) 117 (47.4%)
%) 43 (17.4%)
) 124 (50%)
) 33 (13%)
) 90 (36%)
) 42 (17.0%)
) 16 (7%)
) 104 (42%)
) 65 (26%)
) 37 (15%)
) 25 (10%)
-density lipoprotein.
ymptomatic Menegies for Asymptomatic Men
cremental Costs/QALY ($/QALY)*
Compared With Current Practice‡
Incremental Costs/QALY ($/QALY)*
Compared With Next-Best Strategy‡
Reference Reference
30,278 30,278
42,118 Dominated§
35,977 48,800
ars) who have an intermediate risk (10% to 20%, 10-year risk) of coronary heart disease (CHD).
S. dollars. ‡Because not all strategies are considered feasible in all situations, we have presented
minated by “extended dominance”—implies that there is another strategy (computed tomographyopula
0% a
(n  3
(66–7
(24.8–
(131–1
(70–8
40) [5.
) [1.2
5) [3.7
(15.8
(26.4
(29.5
9 (9%
0 (21%
0 (70%
(5.8%
1 (3%
2 (37%
9 (24%
4 (20%
3 (16%or AsStrat
In
e 70 ye
010 U.
gy. §Do
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blood pressure, and medication use, were determined for
the cohort of individuals at intermediate risk, stratified by
sex. The number of individuals using a statin, antihyper-
tensive, or aspirin under each strategy was determined.
Quality-adjusted life years (QALYs), lifetime costs, in-
cremental cost-effectiveness ratios (ICER) (i.e., addi-
tional costs divided by QALYs gained), and net health
benefit (QALYs minus [costs/willingness-to-pay]) were
calculated for all strategies. Future costs and effectiveness
were discounted, to take into account time preference, at
the currently recommended U.S. discount rate of 3% for
both costs and effectiveness (47,48). To take into account
second-order uncertainty, 100,000 independent samples
were drawn from each of the input parameter distribu-
tions, generating outcome distributions for QALYs and
costs for each strategy. Calculations were done for men
and women separately.
Strategies were first ordered according to increasing
cost. A strategy was considered dominated if another
strategy was both more effective and less costly. A
strategy was considered extended dominated if another
strategy achieved more effectiveness at a lower ICER. The
ICERs were calculated, after eliminating dominated and
extended dominated strategies, as the difference in mean
lifetime costs divided by the difference in mean QALYs
for each strategy compared with the next-best non-
dominated strategy. We considered $50,000/QALY
gained as a commonly accepted threshold for the societal
willingness-to-pay threshold for primary prevention
(49 –51) and varied it between $15,000 and $100,000 in
sensitivity analyses. For the reference case analysis, we
analyzed the model with input parameters as given in
Table 1.
Extensive 1-way, 2-way, multi-way, and probabilistic
sensitivity analyses were performed with plausible ranges of
the parameter values. In particular, we explored model
sensitivity to drug costs, aspirin therapy in women, and the
relative risk of an event with aspirin therapy. Because some
clinicians would be reluctant to withhold therapy from an
individual who starts out with a predicted risk of 11%
(putting him originally at intermediate risk) and—after
inclusion of coronary calcium—a revised risk of 9% (putting
him at low risk), we explored the effect of an alternative
assumption in which treating individuals reclassified to the
5% to 10% risk category as individuals with intermediate
risk (10% to 20%) and checked whether the optimal
decision would change. Reclassification probabilities for this
assumption are presented in Online Table 4.
Because the 2004 guidelines on the initiation of statin
therapy include an optional cutoff value of 100 mg/dl for
individuals at intermediate risk, we did an additional anal-
ysis with this cutoff value in the “current guidelines” strategy
and the “CT calcium screening” strategy for the individuals
who remained in the intermediate-risk group.Probabilistic sensitivity analysis was performed with the
outcome distributions of 100,000 Monte Carlo simulations
(52). We calculated the probability that CT screening was
cost-effective, compared with current practice, current
guidelines, and statin therapy strategies for varying
willingness-to-pay thresholds, which yielded acceptability
curves.
Figure 2 Cost-Effectiveness Plane
(A) Cost-effectiveness plane in men. Quality-adjusted life expectancy in years
against total lifetime costs in U.S. dollars, for computed tomography (CT) coro-
nary calcium screening, current practice, current guidelines, and statin therapy.
Current guidelines are (extended) dominated by CT coronary calcium screening.
(B) Cost-effectiveness plane in women. Quality-adjusted life expectancy in
years against total lifetime costs in U.S. dollars, for CT coronary calcium
screening, current practice, current guidelines, and statin therapy. The CT coro-
nary calcium screening is (extended) dominated by current guidelines.
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October 11, 2011:1690–701 Cost-Effectiveness of CT Calcium ScreeningResults
Reference case analysis. Review of the baseline character-
istics of the cohort at intermediate risk demonstrated that
women were older than men and had less favorable risk
factor levels, apart from smoking and calcium scores (Table 2). In
men, implementing current guidelines for all individuals at
intermediate risk led to a steep increase in the number of
statin and antihypertensive users (from 12% to 75% and
23% to 64%, respectively), compared with current practice
(Online Table 5). In women, a similar pattern was observed
(from 15% to 87% and 52% to 84%, respectively) (Online
Table 6). Implementing the CT screening strategy results in
slightly fewer statin users, compared with implementing
current guidelines in both men (69% vs. 75%) and women
(41% vs. 87%). In men, statin users with either current
practice or CT screening had a higher expected 10-year risk
of CHD compared with nonusers (Online Table 7). This
difference disappeared between users and nonusers with
current guidelines. In women, this was only the case for CT
screening (Online Table 8). In men (Table 3), CT calcium
screening was more effective and more costly compared with
current practice (QALY gain: 0.13 [95% confidence interval
(CI): 0.01 to 0.26], cost-increase: $4,676 [95% CI: $3,126
to $6,339]), more effective and more costly than statin
therapy (QALY gain: 0.04 [95% CI: 0.02 to 0.13], cost
increase: $1,951 [95% CI: $1,170 to $2,754]), and more
effective but slightly more costly than current guidelines
(QALY gain: 0.02 [95% CI: 0.04 to 0.09], cost increase:
$44 [95% CI: $441 to $486]). The cost-effective plane in
igure 2A shows that, in men, current guidelines are
xtended dominated by CT screening, because the latter
eads to a higher expected quality-adjusted life expectancy
gainst a lower incremental cost-effectiveness ratio. The
ncremental cost-effectiveness ratio of statin therapy is
30,278/QALY, and for CT calcium screening it is
48,800/QALY gained (Table 3). In women (Table 4), CT
creening was more effective and more costly than current
ractice (QALY gain: 0.13 [95% CI: 0.02 to 0.28]; cost
ncrease $4,663 [95% CI: $3,120 to $6,277]), more effective
nd more costly than statin therapy (QALY gain: 0.03 [95%
I: 0.03 to 0.12], cost increase: $2,273 [95% CI: $1,475
to $3,109]), and less expensive but also less effective com-
Cost, Clinical Effectiveness, and Cost-Effectiveness of Strategies fTable 4 Cost, Clinical Effectiveness, and Cost-Effectiveness of
Total Lifetime Costs*†
Quality-Adjusted
Life Expectancy* (yrs)
Current practice 8,553 9.26
Statin therapy 10,944 9.36
CT screening 13,216 9.39
Current guidelines 13,514 9.41
Cost, clinical effectiveness, and cost-effectiveness of strategies for asymptomatic women (mean
increasing cost. *Future costs and life years were discounted at 3%/year. †2010 U.S. dollars.
cost-effectiveness ratios compared with both “current practice” and the next-best strategy. §Dom
higher effectiveness at a lower incremental cost-effectiveness ratio.
Abbreviations as in Table 3.pared with current guidelines (QALY loss: 0.02 [95% CI: $0.03 to 0.07], cost savings: $297 [95% CI:$8 to $633]).
he cost-effective plane in Figure 2B shows that, in women,
T screening is extended dominated by current guidelines,
ecause the latter leads to a higher expected quality-adjusted
ife expectancy against a lower incremental cost-effectiveness
atio, and therefore, CT screening is not considered cost-
ffective in women.
ensitivity analysis. In men, at a willingness-to-pay
hreshold of $50,000/QALY, a slight dyssynergy between
rugs would change the optimal decision from CT
creening to statin therapy (Table 5). This shift would
lso occur if treatment adherence dropped below 58%,
he effect of aspirin therapy on CHD was less protective,
he cost of a CT scan rose above $200, or the risk of
adiation-induced cancer increased more than 10-fold. In
omen, the optimal strategy changed from “current
uidelines” to statin therapy in case of a slight dyssynergy
etween drugs. Strong protective effects of aspirin on the
ncidence of CHD and/or stroke would change the
ptimal strategy to “CT screening” (Table 6). Using
eneric drug prices made the CT screening more cost-
ffective in men, with an ICER of $24,675/QALY,
hereas in women current guidelines became more cost-
ffective, with an ICER of $21,140/QALY. Substituting
he statin therapy strategy with the aggressive medical
reatment strategy did not change the optimal decision in
en. In women the optimal decision switched from
urrent guidelines to aggressive medical treatment.
Probabilistic sensitivity analysis demonstrated that, in men,
T screening was cost-effective compared with current prac-
ice in the majority of simulations if the willingness-to-pay
hreshold was above $50,000 (Fig. 3A). In women, even at
igher willingness-to-pay thresholds, CT calcium screening
ould be cost-effective in 20% of the simulations (Fig. 3B).
iscussion
n this study we evaluated the comparative effectiveness and
ost-effectiveness of CT coronary calcium screening within
he framework of current CVD prevention guidelines. In
en, the incremental cost-effectiveness ratio for CT screen-
ng was just below the willingness-to-pay threshold of
ymptomatic Womenegies for Asymptomatic Women
cremental Costs/QALY ($/QALY)*
Compared With Current Practice‡
Incremental Costs/QALY ($/QALY)*
Compared With Next-Best Strategy‡
Reference Reference
23,910 23,910
35,869 Dominated§
33,073 51,400
years) who have an intermediate risk (10% to 20%, 10-year risk) of CHD. Strategies ordered by
se not all strategies are considered feasible in all situations, we have presented incremental
by “extended dominance”—implies that there is another strategy (current guidelines) that yieldsor AsStrat
In
age 74
‡Becau
inated50,000/QALY, and small changes in assumptions changed
1698 van Kempen et al. JACC Vol. 58, No. 16, 2011
Cost-Effectiveness of CT Calcium Screening October 11, 2011:1690–701CT screening from being cost-effective to not cost-effective.
Some of the assumptions could be considered plausible,
such as a slight dyssynergy between drugs or a treatment
adherence lower than 60%, whereas others were more
extreme (e.g., a more than 10-fold increase in radiation
risk). The uncertainty in optimal decision was further
illustrated by the acceptability curves, which showed that, in
a minor but substantial proportion of the simulations, CT
screening was not cost-effective. However, with generic
drug prices the ICER for CT screening dropped, and the
result was more robust in sensitivity analysis.
In women, CT screening was not found to be cost-
effective, even after using a wide range of varying assump-
tions, which included assumptions more favorable to the
CT calcium screening strategy by treating individuals in the
higher end of “low risk” (5% to 10% risk) more aggressively
and with more treat-prone LDL thresholds. The difference
in the optimal decision between men and women can be
explained by the fact that, compared with men, more
women were reclassified to the low-risk group, leading to
less aggressive treatment. Furthermore, within the low-risk
group, the observed risk of CHD is higher in women than
in men, so the foregone benefit with less aggressive treat-
Optimal Strategy in 1-Way Sensitivity Analysis, With a Willingness-Table 5 Optimal Strategy in 1-Way Sensitivity Analysis, With a
Variable of Interest Range Assessed in D
Synergy factor
Treatment adherence
RR of aspirin treatment on CHD
RR of aspirin treatment on stroke
Cost of CT coronary calcium scan
Annual incidence of radiation-induced cancer 1/1
Outcome
Discount rates 4% for co
LDL threshold for statin initiation
Treatment of individuals reclassified to 5%–10% Similar to
Yearly drug prices of statins and antihypertensives Gen
Aggressive medical treatment instead of statin therapy
N/A  not applicable; RR  relative risk; other abbreviations as in Tables 2 and 3.
Optimal Strategy in 1-Way Sensitivity Analysis, With a Willingness-Table 6 Optimal Strategy in 1-Way Sensitivity Analysis, With a
Variable of Interest Range Assessed in De
Synergy factor
Treatment adherence
RR of aspirin treatment on CHD
RR of aspirin treatment on stroke
Cost of CT coronary calcium scan $
Annual incidence of radiation-induced cancer 1/10
Outcome “H
Discount rates 4% for cos
LDL threshold for statin initiation 1
Treatment of individuals reclassified to 5%–10% Similar to
Yearly drug prices of statins and antihypertensives Gene
Aggressive medical treatment instead of statin therapyAbbreviations as in Tables 2, 3 and 5.ment is higher in women. The benefit of CT screening is
obtained in the high-risk group, where individuals are
treated more aggressively compared with current guidelines
for treatment of intermediate-risk individuals. Because
fewer women were reclassified to high risk, the potential
benefit of CT screening is lower than in men. The balance
is further shifted because aspirin is prescribed in men at high
risk but not in women, due to controversy with regard to its
efficacy in primary prevention of CHD.
The Adult Treatment Panel (ATP)-IV guidelines,
which will be published soon, are expected to recommend
more aggressive statin treatment than the current statin
treatment guidelines. Our statin therapy strategy can be
considered quite aggressive and is likely to be similar to
the anticipated ATP-IV recommendation, ensuring fu-
ture applicability of our results. Of note, when we
compared CT screening with an even more aggressive
treatment strategy, as we did in the sensitivity analysis
with the “medical treatment” strategy, CT screening
remained cost-effective in men. This implies that CT
screening does not simply put more individuals on
treatment but allocates treatment to individuals who are
expected to benefit most.
y of $50,000/QALY in Menngness-to-Pay of $50,000/QALY in Men
nistic Sensitivity Analysis Optimal Decision (Base Case: CT Screening)
1.1 Statin therapy if synergy factor 1.02
1.0 Statin therapy if adherence 0.58
1.0 Statin therapy if RR 0.84
1.0 CT screening
600 Statin therapy if cost of CT $200
–1/100 Statin therapy if radiation risk increases 10-fold
HD” CT screening
5% for QALYs CT screening
g/dl CT screening
mediate risk” CT screening
ug prices CT screening
A CT screening
y of $50,000/QALY in Womenngness-to-Pay of $50,000/QALY in Women
istic Sensitivity Analysis Optimal Decision (Base Case: Current Guidelines)
.1 Statin therapy if synergy factor1.02
.0 Current guidelines
.0 CT screening if RR0.73
.0 CT screening if RR0.62
00 Current guidelines
–1/100 Current guidelines
HD” Current guidelines
% for QALYs Current guidelines
/dl Current guidelines
ediate risk” Current guidelines
g prices Current guidelines
Medical treatmentto-PaWilli
etermi
0.9–
0.2–
0.2–
0.2–
$20–$
00,000
“Hard C
sts, 1.
100 m
“inter
eric dr
N/to-PaWilli
termin
0.9–1
0.2–1
0.2–1
0.2–1
20–$6
0,000
ard C
ts, 1.5
00 mg
“interm
ric dru
N/A
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October 11, 2011:1690–701 Cost-Effectiveness of CT Calcium ScreeningA number of cost-effectiveness reports on CT coronary
calcium scoring have previously been published but differed
from our study in the strategies or target population considered
or in that they dichotomized the calcium score rather than
including the score in a risk prediction. These studies found
that cost-effectiveness of CT screening was highly sensitive to
the population screened and downstream costs (53–55). The
Figure 3 Acceptability Curve
(A) Acceptability curve in men. For varying willingness-to-pay thresholds, the
proportions of simulations that demonstrated cost-effectiveness for each strat-
egy, computed tomography (CT) coronary calcium screening, current practice,
current guidelines, and statin therapy, are indicated. (B) Acceptability curve
in women. For varying willingness-to-pay thresholds, the proportions of simu-
lations that demonstrated cost-effectiveness for each strategy, CT coronary cal-
cium screening, current practice, current guidelines, and statin therapy, are
indicated.relatively high incremental cost-effectiveness ratio we found forCT screening in men is comparable to results of other
cost-effectiveness studies on interventions for primary preven-
tion of CHD, such as the study by Pletcher et al. (43).
Generalizability of our findings is further supported by com-
parable reclassification data on coronary calcium found by
Polonsky et al. (7) in the multi-ethnic study of atherosclerosis.
Study limitations. First, we focused on individuals at
intermediate risk, which implied individuals were on aver-
age older than 69 years of age. Screening for coronary
calcium could potentially have value in other subgroups, but
we explicitly chose to investigate CT screening in the
intermediate-risk group as advocated by recent guidelines
and current consensus. Second, the time horizon in our
analysis was the remaining lifetime. Therefore, we had to
extrapolate the incidence of CHD beyond the available
10-year data, but few simulated individuals lived beyond 15
years. Finally, although we stratified by sex, further strati-
fication by different combinations of baseline risk factors
was not possible due to a limited sample size.
As with all models of screening and diagnostic tests, the
differences between the 4 strategies in terms of quality-
adjusted life expectancy were small. Even though, in
women, the results seem robustly unfavorable for the CT
coronary calcium screening strategy, the residual uncertainty
reflected in the acceptability curves indicates that further
research might be beneficial. In men, the results indicated
that CT screening was cost-effective in the majority of
simulations. Nevertheless, in a substantial proportion of
simulations in men, current guidelines or statin therapy was
optimal compared with CT screening, indicating that fur-
ther research is necessary.
Conclusions
Screening for coronary artery calcium with CT is probably
cost-effective in men at intermediate risk of CHD. For
women at intermediate risk for CHD, CT screening does
not seem to be cost-effective.
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